SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Kiora Pharma

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• Nantahala Capital Management, LLC, along with principals Wilmot B. Harkey and Daniel Mack, filed a Schedule 13G reporting beneficial ownership of 438,469 shares of Kiora Pharmaceuticals, Inc. common stock.
• The reported stake represents 9.99% of the company's outstanding common stock.
• The shares include 438,469 shares potentially acquirable within 60 days through the exercise of convertible securities.
• Blackwell Partners LLC Series A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from the sale of more than 5% of these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest in the company's equity, though the reliance on convertible securities introduces potential dilution concerns.

Positives

• Institutional investor confidence indicated by a significant 9.99% equity position.
• The filing confirms the investment was made in the ordinary course of business, suggesting a passive investment strategy.

Negatives

• The stake is held through convertible securities, which may lead to future dilution for existing shareholders upon exercise.

Risks

• Potential for future share dilution if the convertible securities are exercised.
• Market volatility associated with the underlying common stock of a pharmaceutical company.

Future Outlook

The reporting persons have certified that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings of this nature in the pharmaceutical sector often signal long-term interest from specialized healthcare investment firms, though they do not necessarily imply an active role in corporate strategy.

Comparison to Industry Standards

• The 9.99% threshold is a common reporting benchmark for institutional investors to avoid triggering more stringent 'active' reporting requirements under SEC rules.
• Investment in small-cap pharmaceutical companies via convertible debt or equity is a standard strategy for specialized hedge funds like Nantahala.

Related Party Transactions

• Blackwell Partners LLC Series A is identified as a fund advised by Nantahala with rights to dividends or proceeds from the reported shares.

Stakeholder Impact

• Shareholders should be aware of the potential for dilution from the conversion of the reported securities.
• The presence of a significant institutional holder may provide a degree of market stability.

Next Steps

• Monitoring for any future amendments to the Schedule 13G if ownership levels change significantly.
• Tracking potential conversion of the reported securities into common stock.

Key Dates

Keywords

Kiora Pharmaceuticals, Nantahala Capital, Schedule 13G, Institutional Ownership, Biotech Investment, Convertible Securities